Hemant Surgical Industries Ltd (HSIL) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Hemant Surgical Industries Ltd stock ₹134, price ₹570, upside -76.5%, quality 52 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 23, 2026.
How to read this chart
60‑month range ₹91.95 – ₹1,283 · fair‑value band ₹86.65 – ₹208.93 · the ₹570.00 price screens above the ₹133.67 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 23, 2026.
Follow Hemant Surgical Industries in your weekly email
Every Wednesday you see whether Hemant Surgical Industries is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hemant Surgical Industries Ltd (HSIL) currently trades at ₹570.00, while our model-based Fair Value estimate is ₹133.67, 76.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹581.36 per share, and 2 of the 15 models we run sit above the ₹570.00 price.
Bear case: the Asset-Based group reads lowest at ₹38.40, and 13 of the 15 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹86.65 (bear) to ₹208.93 (bull), the price of ₹570.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Consumer Cyclical sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hemant Surgical Industries Ltd reported revenue of ₹2.3B in FY2025 versus ₹180M in FY2021, a compound +89.4%/yr. Reported net income was ₹182M in FY2025, compounding +102.4%/yr from FY2021.
Key figures
Market cap ₹8.3B (≈ $87.6M) Micro · P/E ratio 38.1 · P/S ratio 3.59 · EPS (TTM) ₹14.96 · Net margin 7.9% · Return on equity 18.1% · Return on assets (EBIT) 5.8% · Operating margin 10.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 162% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at −14% fair-value upside, at −77%, HSIL screens richer than that median.
Fair Value models
Bear₹86.65Fair Value ₹133.67Bull₹208.93
Price ₹570.00 · Upside -76.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (₹12.21 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+761.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+113.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+86.5%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+22.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+22.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.80.8% vs 36.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 9%
2025 sits 1,601% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Compare Hemant Surgical Industries Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Hotels & Entertainment Services” was too small, so the broader sector is used.)Consumer Discretionary · 3540 stocks
Beats the sector median on 6/12 measures
A mixed picture versus its sector peers.
Valuation
Quality Score52 · Below median
Fair Value upside−76.5% · Bottom 25%
Profitability
Return on equity (12 months)18.1% · Top 25%
Return on assets6.6% · Top 25%
Net margin (12 months)7.9% · Above median
Operating margin (12 months)10.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)189.4% · Top 25%
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Consumer Discretionary median · lower = cheaper
P/E (12 months)38.1× · Priciest 25%
P/B6.04× · Priciest 25%
P/S (12 months)3.59× · Priciest 25%
EV/EBITDA31.4× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 41
FUTURE (revenue growth)100· sector 22
PAST (return on equity)72· sector 24
HEALTH (low debt)99· sector 95
DIVIDEND (yield)0· sector 49
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hemant Surgical Industries Ltd (HSIL) overvalued or undervalued?
As of Oct 23, 2026, our model estimates a fair value of ₹133.67 versus a price of ₹570.00, about −77% upside (overvalued).
What is the fair value of HSIL?
Our model-based fair value for Hemant Surgical Industries Ltd is ₹133.67 (as of Oct 23, 2026), built from audited fundamentals. The current price: ₹570.00.
What is the quality score of HSIL?
Hemant Surgical Industries Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hemant Surgical Industries Ltd (HSIL)?
Our model-based price target is the fair value of ₹133.67 (as of Oct 23, 2026) from 15 valuation models. Cautious scenario ₹86.65, optimistic scenario ₹208.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Hemant Surgical Industries Ltd stock forecast for 2026?
Our models put fair value at ₹133.67, about −77% upside versus a price of ₹570.00 (overvalued). Cautious scenario ₹86.65, optimistic scenario ₹208.93. The calculation is refreshed regularly with new filings.
What is the revenue of Hemant Surgical Industries Ltd (HSIL)?
Hemant Surgical Industries Ltd reported trailing-twelve-month revenue of about ₹2.3B (latest available figure, as of Oct 23, 2026).
What is the intrinsic value of Hemant Surgical Industries Ltd (HSIL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hemant Surgical Industries Ltd it is ₹133.67 per share (as of Oct 23, 2026), against a price of ₹570.00. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Hemant Surgical Industries Ltd stock overvalued or undervalued in 2026?
As of Oct 23, 2026, HSIL trades above its calculated fair value: price ₹570.00, fair value ₹133.67, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HSIL?
No. The price is what the market pays today (₹570.00); the fair value is what the company's own numbers justify (₹133.67). For Hemant Surgical Industries Ltd the two are ₹436.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hemant Surgical Industries Ltd worth?
The market values Hemant Surgical Industries Ltd at about ₹8.3B (market capitalisation, as of Oct 23, 2026). Per share that is ₹570.00; our models calculate a fair value of ₹133.67 per share.
What do the bullish and bearish scenarios say about HSIL?
Our models span a range for Hemant Surgical Industries Ltd: cautious scenario ₹86.65, base ₹133.67, optimistic ₹208.93 per share (as of Oct 23, 2026, price ₹570.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HSIL?
Hemant Surgical Industries Ltd trades at a price-to-earnings ratio of 38.1 (as of Oct 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹133.67 is built from several models across several years. Other multiples: P/B 6.0, P/S 3.6, EV/EBITDA 31.4.
How solid is the balance sheet of Hemant Surgical Industries Ltd (HSIL)?
Balance-sheet figures for Hemant Surgical Industries Ltd (as of Oct 23, 2026): return on equity 18.1%, debt of 0.02 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is HSIL from its 52-week high?
Hemant Surgical Industries Ltd trades at ₹570.00, about 27% below its 52-week high of ₹782.85 and 162% above the low of ₹217.50 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of ₹133.67 is for.
Which stocks are comparable to Hemant Surgical Industries Ltd?
From the same area (Consumer Cyclical) we also value JFC, BLOOM, Ananti Inc, PIZZA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hemant Surgical Industries Ltd stock attractive at the current price?
The data as of Oct 23, 2026: price ₹570.00, calculated fair value ₹133.67 (−77%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HSIL calculated?
We run Hemant Surgical Industries Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹133.67, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Hemant Surgical Industries Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hemant Surgical Industries Ltd (HSIL)?
The closing price on Oct 23, 2026 was ₹570.00. Our model-based fair value is ₹133.67, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hemant Surgical Industries Ltd right now?
The price sits above even our optimistic bull case (₹208.93). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹86.65 to ₹208.93) leaves room in how you read the outcome.
Key figures of Hemant Surgical Industries Ltd
How large is the market capitalisation of Hemant Surgical Industries Ltd (HSIL)?
The market capitalisation of Hemant Surgical Industries Ltd is ₹8.3B (≈ $87.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hemant Surgical Industries Ltd (HSIL)?
The price-to-sales ratio of Hemant Surgical Industries Ltd is 3.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hemant Surgical Industries Ltd (HSIL)?
Earnings per share at Hemant Surgical Industries Ltd are ₹14.96 (price ÷ EPS = P/E 38.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hemant Surgical Industries Ltd (HSIL)?
The net margin of Hemant Surgical Industries Ltd is 7.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hemant Surgical Industries Ltd (HSIL)?
The return on equity (ROE) of Hemant Surgical Industries Ltd is 18.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hemant Surgical Industries Ltd (HSIL)?
On an EBIT basis the return on assets of Hemant Surgical Industries Ltd is 5.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hemant Surgical Industries Ltd (HSIL)?
The operating margin of Hemant Surgical Industries Ltd is 10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hemant Surgical Industries Ltd (HSIL)?
Revenue at Hemant Surgical Industries Ltd is growing +189% versus a year earlier (3y avg +113%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hemant Surgical Industries Ltd (HSIL)?
Earnings per share at Hemant Surgical Industries Ltd are growing +193% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hemant Surgical Industries Ltd (HSIL) generate?
The free cash flow of Hemant Surgical Industries Ltd is −₹342M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hemant Surgical Industries Ltd (HSIL) carry?
The net debt of Hemant Surgical Industries Ltd is ₹58.1M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hemant Surgical Industries Ltd in the live analysis
One click puts Hemant Surgical Industries Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 23, 2026